PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Recruiting
N/A
Interventional Study
Primary Aldosteronism
Secondary Hypertension
Aldosterone-Producing Adenoma
Idiopathic Hyperaldosteronism
Adrenalectomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- Seoul National University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥19 years
* Diagnosed with PA per 2016 Endocrine Society guidelines
* Underwent adrenal CT
* Signed informed consent
Exclusion Criteria:
* Women who are pregnant, breastfeeding, or may become pregnant
* Individuals who refuse to undergo surgery
* Individuals for whom 68G…
Contacts